Lowest Price Guaranteed From USD 5,899
Published
June 2021
Pages
265
View Count
4992
 |
 |
 |
 |
 |
 |
 |
 |
 |
According to the WHO, cancer is presently the second leading cause of death, worldwide. As per GLOBOCAN, the number of patients diagnosed with various types of cancer in the US, crossed the 19 million mark in 2020. By 2030, it is estimated that the aforementioned number is likely to grow to over 22 million. Over time, it has been established that the conventional approaches, such as chemotherapy, surgery and radiation therapy, to treating oncological indication(s) are inadequate, especially when it comes to late-stage cancers. In fact, several of the traditional interventions are designed to eliminate cancerous tissue by damaging the genetic material (DNA) contained in the malignantly transformed cells, in order to trigger programmed cell death. However, if the therapeutic-induced DNA damage is repaired, the cells survive. This is also the basis for why specific patient populations become resistant to certain forms of therapy. Over the years, scientific enquiry into the genetic causes of the malignant transformation have recognized defects and tumor microenvironment induced upregulation of specific cellular pathways, which are deemed to be responsible for the identification / repair of DNA damage and the resulting resistance to the traditional forms of treatment. These are now considered to be reliable disease biomarkers and thereby, viable biological targets for targeted drug development initiatives.
The DNA damage response (DDR) comprises of orchestrated network of pathways that signal not only for repair of DNA lesions but also for activation of checkpoints, which are responsible for cell arrest at key points in the cell cycle. Importantly, high specificity and sensitivity to conventional therapies, coupled to minimal off target toxicity, have led to the use of DDR as a potential target for treatment of wider range of clinical conditions (both oncological and non-oncological). In this regard, several researchers across the globe have developed / developing DDR inhibitors to overcome DDR-mediated resistance to DNA-damaging anticancer therapy and exploit DDR dysfunction in oncological indication by targeting alternative pathways.
Currently, there are four approved poly-ADP ribose polymerase (PARP) inhibitor drugs that are based on the inhibition of the DNA damage repair process in advanced stage oncological indications. Further, drug developers across the world, claim to be evaluating several other molecular targets, such as ATM, ATR, CHK1, and WEE1, within the DNA damage response pathway. Although majority of the drug candidates for molecular targets (other than PARP) are in the preclinical / initial clinical stages, drug developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Gradually, a substantial body of evidence, validating the efficacy of drugging the aforementioned biological targets, is being generated through extensive research in this field; this is reflected in the rapidly growing number of research publications and patents focused on this subject. Driven by encouraging clinical trial results, this niche, but upcoming market, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.
The “DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market by Target Disease Indication (Acute Myeloid Leukemias, COVID-19, Diabetic Macular Edemas, Mesotheliomas, Myelodysplastic Syndromes, Non-Squamous Non-Small Cell Lung Cancers, Prostate Cancers, Uterine Serous Carcinomas), Therapeutic Area (Hematological Malignancies, Solid Tumors, and Other Disorders), Target Molecule (APE1/Ref-1, Casein Kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), Type of Molecule (Biologics and Small Molecule), Route of Administration (Oral Drugs and Intravenous Drugs), and by Key Geographical Regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of DNA damage response targeting therapeutics in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and future opportunity for DNA damage response targeting therapeutics developers, over the next decade. Further, we have provided an informed estimate of the evolution of the market, during the period 2021-2030, based on several relevant parameters, such as adoption trends, and expected price variations for these products. Additionally, the report features the likely distribution of the current and forecasted opportunity within DNA damage response targeting therapeutics market across [A] target disease indications (acute myeloid leukemias, COVID-19, diabetic macular edemas, mesotheliomas, myelodysplastic syndromes, non-squamous non-small cell lung cancers, prostate cancers, and uterine serous carcinomas), [B] therapeutic areas (hematological malignancies, solid tumors, and other disorders), [C] target molecule (APE/REF-1, casein kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), [D] type of molecule (biologics and small molecule), [E] route of administration (oral drugs and intravenous drugs), and [F] key geographical regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of DNA damage response targeting therapeutics market and its likely evolution in the short to mid-term and long term.
Chapter 3 provides a general introduction to the DNA damage and associated repair systems in the human body. In addition, it features a detailed discussion on the different types of DNA damage that have been identified, along with their respective causes. It also features an elaborate description of DNA repair systems and associated biological pathways that are activated during the detection of damage within the cell’s genetic code. Further, it provides a discussion on the potential therapeutic benefits of targeting defects in DNA repair pathways for the treatment of different disease indications, such as cancer.
Chapter 4 includes a detailed analysis of the current market landscape of over 105 DNA damage response targeting therapeutics, based on phase of development (clinical and preclinical), target disease indication(s), therapeutic areas (hematological malignancies, immune-oncological disorders, neurological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological, and small molecules), type of therapy (monotherapies, and combination therapies), dosage form (liquid, and solid), route of administration (intravenous, subcutaneous, and oral), and special drug designation awarded (if any). In addition, it highlights the companies engaged in the development of DNA damage response targeting therapeutics, along with information on their year of establishment, company size (in terms of employee count), and location of respective headquarters.
Chapter 5 highlights the contemporary market trends in four schematic representations, including [A] a bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as product portfolio strength, phase of development and company size), [B] an insightful tree map representation of DNA damage response targeting therapeutics developers, based on their target therapeutic area and company size, [C] a world map representation highlighting the regional distribution of developers engaged in this domain, and [D] a grid representation illustrating the distribution of DNA damage response targeting therapeutics based on their phase of development, target therapeutic area, type of molecule, type of therapy, and route of administration.
Chapter 6 features elaborate profiles of prominent players engaged in development of DNA damage response targeting therapeutics. Each profile features a brief overview of the company details related to its respective drug candidates, recent developments and an informed future outlook.
Chapter 7 presents a detailed clinical trial analysis of DNA damage response targeting therapeutics taking into consideration several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status, and study design, highlighting leading sponsors / collaborators and leading players (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful case study (for trials related to clinical DNA damage response targeting therapeutics, within the scope of the report).
Chapter 8 provides a detailed analysis of over 150 peer-reviewed scientific articles related to DNA damage response targeting therapeutics, published during the period April 2020- March 2021. The analysis takes into consideration target molecules, and analysis based on several relevant parameters, such as year of publication, type of publication, emerging focus area, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor). Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of publication, grant support, journal impact factor, and number of target molecules under study.
Chapter 9 features an insightful multivariate scenario management analysis impacting adoption rates and price points taking into consideration more than 20 parameters.
Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of DNA damage response targeting therapeutics market till 2030. We have segmented the market across [A] target disease indications (acute myeloid leukemias, COVID-19, diabetic macular edemas, mesotheliomas, myelodysplastic syndromes, non-squamous non-small cell lung cancers, prostate cancers, and uterine serous carcinomas), [B] therapeutic area (hematological malignancies, solid tumors, and others), [C] target molecule (APE/REF-1, casein kinase 2, CHK-1, C-Tak, DHODH, p53, MAPKAPK2, and WEE 1), [D] type of molecule (biologics and small molecule), [E] route of administration (oral drugs and intravenous drugs), and [F] key geographical regions (US, Canada, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of DNA Damage
3.3. DNA Damaging Agents
3.4. DNA Damage Response Systems
3.4.1. Key Components of DNA Repair Pathways
3.5. Types of DNA Repair Pathways
3.5.1. Direct Pathways
3.5.2. Excision Repair Pathway
3.5.2.1. Base Excision Repair Pathway
3.5.2.2. Nucleotide Excision Repair Pathway
3.5.2.3. Mismatch Repair Pathway
3.5.3. Indirect Pathways
3.5.3.1. Homologous Recombination (HR) Repair Pathway
3.5.3.2. Non-homologous End Joining (NHEJ) Repair Pathway
3.6. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Damage Response Targeting Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication(s)
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Molecule
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Dosage Form
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Special Drug Designation Awarded
4.3. DNA Damage Response Targeting Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Disease Indication(s)
4.3.3. Analysis by Therapeutic Area
4.3.4. Analysis by Type of Molecule
4.3.5. Analysis by Type of Therapy
4.4 DNA Damage Response Targeting Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Leading Developers: Analysis by Number of Proprietary Product Candidates
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Portfolio Strength, Phase of Development and Company Size (4D Bubble Chart)
5.3. Analysis by Therapeutic Area and Company Size (Treemap Representation)
5.4. Analysis by Location of Headquarters (World Map Representation)
5.5. Analysis by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration (Grid Representation)
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Aprea Therapeutics
6.2.1. Company Overview
6.2.2. DNA Damage Response Targeting Therapeutics Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. AstraZeneca
6.3.1 Company Overview
6.3.2. DNA Damage Response Targeting Therapeutics Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Chordia Therapeutics
6.4.1 Company Overview
6.4.2. DNA Damage Response Targeting Therapeutics Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Mission Therapeutics
6.5.1 Company Overview
6.5.2. DNA Damage Response Targeting Therapeutics Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Repare Therapeutics
6.6.1 Company Overview
6.6.2. DNA Damage Response Targeting Therapeutics Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Senhwa Biosciences
6.7.1 Company Overview
6.7.2. DNA Damage Response Targeting Therapeutics Portfolio
6.7.3. Recent Developments and Future Outlook
7. CLINICAL TRIALS ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. DNA Damage Response Targeting Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Number of Patients Enrolled
7.3.3. Analysis by Gender of Patients Enrolled
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Recruitment Status
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Analysis by Therapeutic Area
7.3.9. Reginal Analysis
7.3.10. Case Study
7.3.11. Most Active Industry Players: Analysis by Number of Clinical Trails
7.3.12. Concluding Remarks
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. DNA Damage Response Targeting Therapeutics: List of Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Type of Publication
8.3.3. Emerging Focus Areas
8.3.4. Analysis by Key Research Journals
8.3.4.1. Most Prominent Journals: Analysis by Number of Publications
8.3.4.2. Analysis by Journal Impact Factor
8.3.4.3. Most Prominent Journals: Analysis by Journal Impact Factor
8.3.5. Analysis by Key Research Hubs
8.3.6. Analysis by Target Molecule
8.3.6.1. Most Popular Target Molecule: Analysis by Number of Publications
8.3.6.2. Analysis by Year and Target Molecule
8.3.7. Analysis by Grants Awarded
8.3.7.1. Locations of Grant Awarding Organizations: Analysis by Number of Publications
8.3.8. Publication Benchmarking Analysis
9. ANALYSIS OF KEY PARAMETERS IMPACTING DRUG PRICING AND ADOPTION
9.1. Chapter Overview
9.2. Key Market Drivers
9.3. Roots Analysis Framework
9.3.1. Benchmarking Parameters
9.3.2. Methodology
9.3.3. Impact on Price and Adoption
9.3.4. Impact on Pricing and Adoption of Individual Drugs / Drug Candidates
9.3.4.1. Adavosertib
9.3.4.2. APX3330
9.3.4.3. ASLAN003
9.3.4.4. CBP-501
9.3.4.5. Eprenetapopt
9.3.4.6. Irofulven
9.3.4.7. LB-100
9.3.4.8. Silmitasertib
9.3.4.9. TRC-102
9.3.5. Concluding Remarks
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Forecast Methodology and Key Assumptions
10.4. Global DNA Damage Response Targeting Therapeutics Market, 2021-2030
10.4.1. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
10.4.1.1. DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, 2021-2030
10.4.1.2. DNA Damage Response Targeting Therapeutics Market for COVID-19, 2021-2030
10.4.1.3. DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, 2021-2030
10.4.1.4. DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, 2021-2030
10.4.1.5. DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, 2021-2030
10.4.1.6. DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, 2021-2030
10.4.1.7. DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, 2021-2030
10.4.1.8. DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, 2021-2030
10.4.2. DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area, 2021 and 2030
10.4.2.1. DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, 2021-2030
10.4.2.2. DNA Damage Response Targeting Therapeutics Market for Solid Tumors, 2021-2030
10.4.2.3. DNA Damage Response Targeting Therapeutics Market for Other Disorders, 2021-2030
10.4.3. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule, 2021 and 2030
10.4.3.1. DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, 2021-2030
10.4.3.2. DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, 2021-2030
10.4.3.3. DNA Damage Response Targeting Therapeutics Market for CHK-1, 2021-2030
10.4.3.4. DNA Damage Response Targeting Therapeutics Market for C-Tak, 2021-2030
10.4.3.5. DNA Damage Response Targeting Therapeutics Market for DHODH, 2021-2030
10.4.3.6. DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, 2021-2030
10.4.3.7. DNA Damage Response Targeting Therapeutics Market for p53, 2021-2030
10.4.3.8. DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, 2021-2030
10.4.3.9. DNA Damage Response Targeting Therapeutics Market for WEE1, 2021-2030
10.4.4. DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule, 2021 and 2030
10.4.4.1. DNA Damage Response Targeting Therapeutics Market for Biologics, 2021-2030
10.4.4.2. DNA Damage Response Targeting Therapeutics Market for Small Molecules, 2021-2030
10.4.5. DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
10.4.5.1. DNA Damage Response Targeting Therapeutics Market for Oral Drugs, 2021-2030
10.4.5.2. DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, 2021-2030
10.4.6. DNA Damage Response Targeting Therapeutics Market: Distribution by Geography, 2021 and 2030
10.4.6.1. DNA Damage Response Targeting Therapeutics Market in the US, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Canada, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Denmark, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in France, 2021-2030
10.4.6.3. DNA Damage Response Targeting Therapeutics Market in Germany, 2021-2030
10.4.6.4. DNA Damage Response Targeting Therapeutics Market in Italy, 2021-2030
10.4.6.5. DNA Damage Response Targeting Therapeutics Market in Spain, 2021-2030
10.4.6.6. DNA Damage Response Targeting Therapeutics Market in the UK, 2021-2030
10.4.6.7. DNA Damage Response Targeting Therapeutics Market in Australia, 2021-2030
10.4.6.8. DNA Damage Response Targeting Therapeutics Market in Singapore, 2021-2030
10.4.6.9. DNA Damage Response Targeting Therapeutics Market in South Korea, 2021-2030
10.4.7. Drug-wise Sales Forecast
10.4.6.1 Adavosertib (AZD1775, MK-1775), AstraZeneca
10.4.6.1.1. Target Patient Population
10.4.6.1.2. Sales Forecast
10.4.6.1.3. Net Present Value
10.4.6.1.4. Value Creation Analysis
10.4.6.2. APX3330, Apexian Pharmaceuticals
10.4.6.2.1. Target Patient Population
10.4.6.2.2. Sales Forecast
10.4.6.2.3. Net Present Value
10.4.6.2.4. Value Creation Analysis
10.4.6.3. ASLAN003 (LAS 186323), Aslan Pharmaceuticals
10.4.6.3.1. Target Patient Population
10.4.6.3.2. Sales Forecast
10.4.6.3.3. Net Present Value
10.4.6.3.4. Value Creation Analysis
10.4.6.4. CBP-501, CanBas
10.4.6.4.1. Target Patient Population
10.4.6.4.2. Sales Forecast
10.4.6.4.3. Net Present Value
10.4.6.4.4. Value Creation Analysis
10.4.6.5. Eprenetapopt, Aprea Therapeutics
10.4.6.5.1. Target Patient Population
10.4.6.5.2. Sales Forecast
10.4.6.5.3. Net Present Value
10.4.6.5.4. Value Creation Analysis
10.4.6.6. Irofulven, Allarity Therapeutics
10.4.6.6.1. Target Patient Population
10.4.6.6.2. Sales Forecast
10.4.6.6.3. Net Present Value
10.4.6.6.4. Value Creation Analysis
10.4.6.7. LB-100 (Lixte Biotechnology)
10.4.6.7.1. Target Patient Population
10.4.6.7.2. Sales Forecast
10.4.6.7.3. Net Present Value
10.4.6.7.4. Value Creation Analysis
10.4.6.8. Silmitasertib, Senhwa Biosciences
10.4.6.8.1. Target Patient Population
10.4.6.8.2. Sales Forecast
10.4.6.8.3. Net Present Value
10.4.6.8.4. Value Creation Analysis
10.4.9 Concluding Remarks
11. CONCLUDING REMARKS
12. APPENDIX I: TABULATED DATA
13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
Figure 3.1 Type of DNA Damage
Figure 3.2 Types of Causative Agents for DNA Damage
Figure 3.3 DNA Damage Causative Agents and Associated Repair System
Figure 3.4 DNA Damage Response System
Figure 3.5 Direct DNA Damage Repair Systems
Figure 3.6 Key Steps Involved in Base Excision Repair Pathway
Figure 3.7 Key Steps Involved in Nucleotide Excision Repair Pathway
Figure 3.8 Key Steps Involved in Mismatch Repair Pathway
Figure 3.9 Key Steps Involved in Homologous Recombination Repair Pathway
Figure 3.10 Key Steps Involved in Non-Homologous Repair Pathway
Figure 4.1 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development
Figure 4.2 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.3 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.4 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Therapeutic Area
Figure 4.5 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution Phase of Development and Therapeutic Area
Figure 4.6 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule
Figure 4.7 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Figure 4.8 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Molecule
Figure 4.9 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule and Type of Molecule
Figure 4.10 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Therapy
Figure 4.11 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Dosage Form
Figure 4.12 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Route of Administration
Figure 4.13 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Special Drug Designation Awarded
Figure 4.14 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Figure 4.15 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.16 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.17 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Figure 4.18 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Figure 4.19 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Therapy
Figure 4.20 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Dosage Form
Figure 4.21 DNA Damage Response Targeting Therapeutics Developers: Distribution by Year of Establishment
Figure 4.22 DNA Damage Response Targeting Therapeutics Developers: Distribution by Company Size
Figure 4.23 DNA Damage Response Targeting Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.24 Leading Developers: Distribution by Number of DNA Damage Response Targeting Therapeutics
Figure 5.1 4D Bubble Representation: Distribution by Portfolio Strength, Target Molecule, Phase of Development and Company Size
Figure 5.2 Treemap Representation: Distribution by Therapeutic Area and Company Size
Figure 5.3 World Map Representation: Distribution by Location of Headquarters
Figure 5.4 Grid Representation: Distribution by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, 2011-2020
Figure 7.3 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Registration Year, 2011-2020
Figure 7.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Gender
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.6 Clinical Trial Analysis: Year wise Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 7.8 Clinical Trial Analysis: Year wise Distribution of Patients Enrolled by Trial Phase
Figure 7.9 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Figure 7.10 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 7.11 Clinical Trial Analysis: Cumulative Year wise Distribution by Recruitment Status
Figure 7.12 Clinical Trial Analysis: Distribution by Study Design
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.14 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15 Clinical Trial Analysis: Year wise Distribution by Most Popular Therapeutic Areas
Figure 7.16 Clinical Trial Analysis: Cumulative Year wise Trend of Patients Enrolled by Most Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Distribution by Therapeutic Area and Average Completion Time
Figure 7.18 Clinical Trial Analysis: Regional Distribution
Figure 7.19 Clinical Trial Analysis: Regional Distribution by Trial Phase and Average Completion Time
Figure 7.20 Clinical Trial Analysis: Regional Distribution by Therapeutic Area and Average Completion Time
Figure 7.21 Clinical Trial Analysis: Regional Distribution by Patients Enrolled
Figure 7.22 Clinical Trial Analysis: Regional Distribution by Average Completion Time
Figure 7.23 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Figure 7.24 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 7.25 Clinical Trial Analysis: Concluding Remarks
Figure 8.1 Publications Analysis: Methodology
Figure 8.2 Publications Analysis: Distribution by Year of Publication
Figure 8.3 Publications Analysis: Distribution by Type of Publication
Figure 8.4 Publications Analysis: Emerging Focus Areas
Figure 8.5 Key Journals: Distribution by Number of Publications
Figure 8.6 Publications Analysis: Distribution by Journal Impact Factor
Figure 8.7 Key Journals: Distribution by Journal Impact Factor
Figure 8.8 Key Research Hubs: Distribution by Number of Publications
Figure 8.9 Publications Analysis: Distribution by Target Molecule
Figure 8.10 Publications Analysis: Year wise Distribution by Most Popular Target Molecules
Figure 8.11 Locations of Grant Awarding Organizations: Distribution by Number of Publications
Figure 8.12 Publications Analysis: Multivariate Benchmark Analysis
Figure 9.1 Key Parameters Impacting Drug Pricing and Adoption
Figure 9.2 Adavosertib (AZD1775) (MK-1775)
Figure 9.3 APX3330
Figure 9.4 ASLAN003
Figure 9.5 CBP-501
Figure 9.5 Eprenetapopt
Figure 9.6 Irofulven
Figure 9.7 LB-100
Figure 9.8 Silmitasertib
Figure 9.9 TRC-102
Figure 10.1 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Figure 10.2 DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
Figure 10.3 DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, 2021-2030 (USD Million)
Figure 10.4 DNA Damage Response Targeting Therapeutics Market for COVID-19, 2021-2030 (USD Million)
Figure 10.5 DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, 2021-2030 (USD Million)
Figure 10.6 DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, 2021-2030 (USD Million)
Figure 10.7 DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, 2021-2030 (USD Million)
Figure 10.8 DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, 2021-2030 (USD Million)
Figure 10.9 DNA Damage Response Targeting Therapeutics Market for Prostate Cancer, 2021-2030 (USD Million)
Figure 10.10 DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, 2021-2030 (USD Million)
Figure 10.11 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 10.12 DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, 2021-2030 (USD Million)
Figure 10.13 DNA Damage Response Targeting Therapeutics Market for Solid Tumors, 2021-2030 (USD Million)
Figure 10.14 DNA Damage Response Targeting Therapeutics Market for Other Disorders, 2021-2030 (USD Million)
Figure 10.15 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule, 2021 and 2030
Figure 10.16 DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, 2021-2030 (USD Million)
Figure 10.17 DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, 2021-2030 (USD Million)
Figure 10.18 DNA Damage Response Targeting Therapeutics Market for CHK-1, 2021-2030 (USD Million)
Figure 10.19 DNA Damage Response Targeting Therapeutics Market for C-Tak, 2021-2030 (USD Million)
Figure 10.20 DNA Damage Response Targeting Therapeutics Market for DHODH, 2021-2030 (USD Million)
Figure 10.21 DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, 2021-2030 (USD Million)
Figure 10.22 DNA Damage Response Targeting Therapeutics Market for p53, 2021-2030 (USD Million)
Figure 10.23 DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, 2021-2030 (USD Million)
Figure 10.24 DNA Damage Response Targeting Therapeutics Market for WEE 1, 2021-2030 (USD Million)
Figure 10.25 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule, 2021 and 2030
Figure 10.26 DNA Damage Response Targeting Therapeutics Market for Biologics, 2021-2030 (USD Million)
Figure 10.27 DNA Damage Response Targeting Therapeutics Market for Small Molecules, 2021-2030 (USD Million)
Figure 10.28 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
Figure 10.29 DNA Damage Response Targeting Therapeutics Market for Oral Drugs, 2021-2030 (USD Million)
Figure 10.30 DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, 2021-2030 (USD Million)
Figure 10.31 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Geography, 2021 and 2030
Figure 10.32 DNA Damage Response Targeting Therapeutics Market in the US, 2021-2030 (USD Million)
Figure 10.33 DNA Damage Response Targeting Therapeutics Market in Canada, 2021-2030 (USD Million)
Figure 10.34 DNA Damage Response Targeting Therapeutics Market in Denmark, 2021-2030 (USD Million)
Figure 10.35 DNA Damage Response Targeting Therapeutics Market in France, 2021-2030 (USD Million)
Figure 10.36 DNA Damage Response Targeting Therapeutics Market in Germany, 2021-2030 (USD Million)
Figure 10.37 DNA Damage Response Targeting Therapeutics Market in Italy, 2021-2030 (USD Million)
Figure 10.38 DNA Damage Response Targeting Therapeutics Market in Spain, 2021-2030 (USD Million)
Figure 10.39 DNA Damage Response Targeting Therapeutics Market in the UK, 2021-2030 (USD Million)
Figure 10.40 DNA Damage Response Targeting Therapeutics Market in Australia, 2021-2030 (USD Million)
Figure 10.41 DNA Damage Response Targeting Therapeutics Market in Singapore, 2021-2030 (USD Million)
Figure 10.42 DNA Damage Response Targeting Therapeutics Market in South Korea, 2021-2030 (USD Million)
Figure 10.43 Adavosertib (AZD1775, MK-1775), AstraZeneca: Sales Forecast, till 2030 (USD Million)
Figure 10.44 APX3330, Apexian Pharmaceuticals: Sales Forecast, till 2030 (USD Million)
Figure 10.45 ASLAN003 (LAS 186323), Aslan Pharmaceuticals: Sales Forecast, till 2030 (USD Million)
Figure 10.46 CBP-501, CanBas: Sales Forecast, till 2030 (USD Million)
Figure 10.47 Eprenetapopt (APR-246), Aprea Therapeutics: Sales Forecast, till 2030 (USD Million)
Figure 10.48 Irofulven, Allarity Therapeutics: Sales Forecast, till 2030 (USD Million)
Figure 10.49 LB-100, Lixte Biotechnology: Sales Forecast, till 2030 (USD Million)
Figure 10.50 Silmitasertib, Senhwa Biosciences: Sales Forecast, till 2030 (USD Million)
Figure 10.51 Global DNA Damage Response Targeting Therapeutics Market, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 11.1 Concluding Remarks: Market Landscape
Figure 11.2 Concluding Remarks: Clinical Trial Analysis
Figure 11.3 Concluding Remarks: Publications
Figure 11.4 Concluding Remarks: Key Parameters Impacting Drug Pricing and Adoption
Figure 11.5 Concluding Remarks: Market Forecast
Table 3.1 Key Components of DNA Repair System
Table 3.2 Comparison of HRR and NHEJ DNA Damage Repair Pathways
Table 3.3 DNA Damage Repair Related Inherited Mutations
Table 4.1 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Phase of Development, Target Disease Indication(s), and Therapeutic Area
Table 4.2 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Target Molecule, Type of Molecule, and Type of Therapy
Table 4.3 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Dosage Form, Route of Administration, and Special Drug Designation Awarded
Table 4.4 DNA Damage Response Targeting Therapeutics (Preclinical Pipeline): Information on Phase of Development, Target Disease Indication(s), and Therapeutic Area
Table 4.5 DNA Damage Response Targeting Therapeutics (Preclinical Pipeline): Information on Target Molecule, Type of Molecule, Type of Therapy and Dosage Form
Table 4.6 DNA Damage Response Targeting Therapeutics: List of Drug Developers
Table 6.1 DNA Damage Response Targeting Therapeutics: List of Companies Profiled
Table 6.2 Aprea Therapeutics: Company Overview
Table 6.3 Aprea Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.4 Aprea Therapeutics: Recent Developments and Future Outlook
Table 6.5 AstraZeneca: Company Overview
Table 6.6 AstraZeneca: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.7 AstraZeneca: Recent Developments and Future Outlook
Table 6.8 Chordia Therapeutics: Company Overview
Table 6.9 Chordia Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.10 Chordia Therapeutics: Recent Developments and Future Outlook
Table 6.11 Mission Therapeutics: Company Overview
Table 6.12 Mission Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.13 Mission Therapeutics: Recent Developments and Future Outlook
Table 6.14 Repare Therapeutics: Company Overview
Table 6.15 Repare Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.16 Repare Therapeutics: Recent Developments and Future Outlook
Table 6.17 Senhwa Biosciences: Company Overview
Table 6.18 Senhwa Biosciences: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.19 Senhwa Biosciences: Recent Developments and Future Outlook
Table 8.1 List of Recent Publications, April 2020 – March 2021
Table 8.2 Publication Analysis: List of Most Valued Publications
Table 10.1 DNA Damage Response Targeting Therapeutics: Promising Drug Candidates
Table 10.2 DNA Damage Response Targeting Therapeutics Forecast Assumptions: Price Estimations in Key Geographies
Table 10.3 Adavosertib (AZD1775, MK-1775), AstraZeneca: Target Patient Population
Table 10.4 Adavosertib (AZD1775, MK-1775), AstraZeneca: Net Present Value (USDMillion)
Table 10.5 Adavosertib (AZD1775, MK-1775), AstraZeneca: Value Creation Analysis (USDMillion)
Table 10.6 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Target Patient Population
Table 10.7 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Net Present Value (USDMillion)
Table 10.8 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Value Creation Analysis(USD Million)
Table 10.9 CBP-501, CanBas: Target Patient Population
Table 10.10 CBP-501, CanBas: Net Present Value (USD Million)
Table 10.11 CBP-501, CanBas: Value Creation Analysis (USD Million)
Table 10.12 Eprenetapopt (APR-246), Aprea Therapeutics: Target Patient Population
Table 10.13 Eprenetapopt (APR-246), Aprea Therapeutics: Net Present Value (USD Million)
Table 10.14 Eprenetapopt, (APR-246) Aprea Therapeutics: Value Creation Analysis (USD Million)
Table 10.15 Irofulven, Allarity Therapeutics: Target Patient Population
Table 10.16 Irofulven, Allarity Therapeutics: Net Present Value (USD Million)
Table 10.17 Irofulven, Allarity Therapeutics: Value Creation Analysis (USD Million)
Table 10.18 LB-100, Lixte Biotechnology: Target Patient Population
Table 10.19 LB-100, Lixte Biotechnology: Net Present Value (USD Million)
Table 10.20 LB-100, Lixte Biotechnology: Value Creation Analysis (USD Million)
Table 10.21 Sapacitabine, Cyclacel Pharmaceuticals: Target Patient Population
Table 10.22 Sapacitabine, Cyclacel Pharmaceuticals: Net Present Value (USD Million)
Table 10.23 Sapacitabine, Cyclacel Pharmaceuticals: Value Creation Analysis (USD Million)
Table 10.24 Silmitasertib, Senhwa Biosciences: Target Patient Population
Table 10.25 Silmitasertib, Senhwa Biosciences: Net Present Value (USD Million)
Table 10.26 Silmitasertib, Senhwa Biosciences: Value Creation Analysis (USD Million)
Table 10.27 TRC-102, TRACON Pharmaceuticals: Target Patient Population
Table 10.28 TRC-102, TRACON Pharmaceuticals: Net Present Value (USD Million)
Table 10.29 TRC-102, TRACON Pharmaceuticals: Value Creation Analysis (USD Million)
Table 12.1 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development
Table 12.2 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.3 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Table 12.4 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Therapeutic Area
Table 12.5 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.6 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule
Table 12.7 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Table 12.8 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Molecule
Table 12.9 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule and Type of Molecule
Table 12.10 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Therapy
Table 12.11 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Dosage Form
Table 12.12 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Route of Administration
Table 12.13 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Table 12.14 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.15 DNA Damage Response Targeting Therapeutics: (Preclinical-stage Drug Candidates) Distribution by Phase of Development and Target Disease Indication(s)
Table 12.16 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Table 12.17 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.18 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Therapy
Table 12.19 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Dosage Form
Table 12.20 DNA Damage Response Targeting Therapeutics Developers: Distribution by Year of Establishment
Table 12.21 DNA Damage Response Targeting Therapeutics Developers: Distribution by Company Size
Table 12.22 DNA Damage Response Targeting Therapeutics Developers: Distribution by Location of Headquarters
Table 12.23 Leading Developers: Distribution by Number of DNA Damage Response Targeting Therapeutics
Table 12.24 4D Bubble Analysis: Distribution by Portfolio Strength, Target Molecule, Phase of Development and Company Size
Table 12.25 Treemap Representation: Distribution by Therapeutic Area and Company Size
Table 12.26 World Map Representation: Distribution by Location of Headquarters
Table 12.27 Grid Representation: Distribution by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration
Table 12.28 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, 2011-2020
Table 12.29 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Registration Year, 2011-2020
Table 12.30 Clinical Trial Analysis: Distribution of Patients Enrolled by Gender
Table 12.31 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.32 Clinical Trial Analysis: Distribution by Year wise Distribution by Trial Phase
Table 12.33 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Table 12.34 Clinical Trial Analysis: Year wise Distribution of Patients Enrolled by Trial Phase
Table 12.35 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Table 12.36 Clinical Trial Analysis: Distribution by Recruitment Status
Table 12.37 Clinical Trial Analysis: Cumulative Year-wise Trend by Recruitment Status
Table 12.38 Clinical Trial Analysis: Distribution by Study Design
Table 12.39 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.40 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 12.41 Clinical Trial Analysis: Year wise Distribution by Most Popular Therapeutic Areas
Table 12.42 Clinical Trial Analysis: Cumulative Year wise Trend of Patients Enrolled by Most Popular Therapeutic Areas
Table 12.43 Clinical Trial Analysis: Distribution by Therapeutic Area and Average Completion Time
Table 12.44 Clinical Trial Analysis: Regional Distribution of Patients Enrolled by Gender
Table 12.45 Clinical Trial Analysis: Regional Distribution by Trial Phase and Average Completion Time
Table 12.46 Clinical Trial Analysis: Regional Distribution by Therapeutic Area and Average Completion Time
Table 12.47 Clinical Trial Analysis: Regional Distribution by Patients Enrolled
Table 12.48 Clinical Trial Analysis: Regional Distribution by Average Completion Time
Table 12.49 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Table 12.50 Leading Industry Players: Distribution by Number of Clinical Trials
Table 12.51 Clinical Trial Analysis: Concluding Remarks
Table 12.52 Publications Analysis: Distribution by Year of Publication
Table 12.53 Publications Analysis: Distribution by Type of Publication
Table 12.54 Key Journals: Distribution by Number of Publications
Table 12.55 Publications Analysis: Distribution by Journal Impact Factor
Table 12.56 Key Journals: Distribution by Journal Impact Factor
Table 12.57 Key Research Hubs: Distribution by Number of Publications
Table 12.58 Publications Analysis: Distribution by Target Molecule
Table 12.59 Publications Analysis: Distribution by Year wise Distribution by Most Popular Target Molecules
Table 12.60 Locations of Grant Awarding Organizations: Distribution by Number of Publications
Table 12.61 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.62 DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
Table 12.63 DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.64 DNA Damage Response Targeting Therapeutics Market for COVID-19, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.65 DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.66 DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.67 DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.68 DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.69 DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.70 DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.71 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area, 2021 and 2030
Table 12.72 DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.73 DNA Damage Response Targeting Therapeutics Market for Solid Tumors, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.74 DNA Damage Response Targeting Therapeutics Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.75 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule, 2021 and 2030
Table 12.76 Damage Response Targeting Therapeutics Market for APE1/Ref-1, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.77 Damage Response Targeting Therapeutics Market for Casein Kinase 2, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.78 Damage Response Targeting Therapeutics Market for CHK-1, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.79 Damage Response Targeting Therapeutics Market for C-Tak, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.80 Damage Response Targeting Therapeutics Market for DHODH, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.81 Damage Response Targeting Therapeutics Market for MAPKAPK2, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.82 Damage Response Targeting Therapeutics Market for p53, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.83 Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.84 Damage Response Targeting Therapeutics Market for WEE 1, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.85 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule, 2021 and 2030
Table 12.86 DNA Damage Response Targeting Therapeutics Market for Biologics, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.87 DNA Damage Response Targeting Therapeutics Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.88 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
Table 12.89 DNA Damage Response Targeting Therapeutics Market for Oral Drugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.90 DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.91 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Geography, 2021 and 2030
Table 12.92 DNA Damage Response Targeting Therapeutics Market in the US, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.93 DNA Damage Response Targeting Therapeutics Market in the Canada, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.94 DNA Damage Response Targeting Therapeutics Market in the Denmark, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.95 DNA Damage Response Targeting Therapeutics Market in France, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.96 DNA Damage Response Targeting Therapeutics Market in Germany, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.97 DNA Damage Response Targeting Therapeutics Market in Italy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.98 DNA Damage Response Targeting Therapeutics Market in Spain, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.99 DNA Damage Response Targeting Therapeutics Market in the UK, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.100 DNA Damage Response Targeting Therapeutics Market in Australia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.101 DNA Damage Response Targeting Therapeutics Market in Singapore, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.102 DNA Damage Response Targeting Therapeutics Market in South Korea, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.103 Adavosertib (AZD1775, MK-1775), AstraZeneca: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 12.104 APX3330, Apexian Pharmaceuticals: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.105 ASLAN003 (LAS 186323), Aslan Pharmaceuticals: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.106 CBP-501, CanBas: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.107 Eprenetapopt, Aprea Therapeutics: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.108 Irofulven, Allarity Therapeutics: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.109 LB-100, Lixte Biotechnology: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.110 Silmitasertib, Senhwa Biosciences: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.111 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES